SCHEMBL3948474

SCHEMBL3948474

CNc1ccn2c(C(=O)c3ccc([N+](=O)[O-])c(OC)c3)c(C)c(C(=O)O)c2c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.39
▸ KMT2A Q03164 6/20 0.39
▸ LMNA P02545 3/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CDC25B P30305 1/20 0.38
▸ MAPT P10636 7/20 0.38
▸ MEN1 O00255 5/20 0.38
▸ TSHR P16473 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ TTR P02766 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HCAR3 P49019 1/20 0.35
▸ HPGD P15428 2/20 0.35
▸ SIRT6 Q8N6T7 1/20 0.35
▸ AKR1C3 P42330 1/20 0.35
▸ AKR1C2 P52895 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3948472 1.00 KDM4E (0.41) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3945586 0.91 KDM4E (0.40) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3945589 0.91 KDM4E (0.40) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3941738 0.88 ALDH1A1 (0.51) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3941735 0.88 ALDH1A1 (0.51) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3953772 0.87 ALDH1A1 (0.38) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3953372 0.87 ALDH1A1 (0.38) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3949479 0.87 ALDH1A1 (0.40) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3949474 0.87 ALDH1A1 (0.40) KDM4EALDH1A1KMT2ALMNAMAPK1
SCHEMBL3953648 0.85 ALDH1A1 (0.39) KDM4EALDH1A1KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 — — US disclosed
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2006-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives FGF1, FGF2, FGFR1 KDM4E 1804/4885ALDH1A1 724/4885KMT2A 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback